http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#Head
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#provenance
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#pubinfo
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion
http://purl.obolibrary.org/obo/DOID_9538
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9538
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB08910
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
http://www.w3.org/2000/01/rdf-schema#label
pomalyst is a thalidomide analogue indicated in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy 1 1 pomalyst in combination with dexamethasone is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 6 days of completion of the last therapy
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB08910
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#provenance
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#pubinfo
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig
http://purl.org/nanopub/x/hasSignature
eexbn+e6FdL1dTmywQbI2yGrIwH4DENS8j594/Rnj4wpiyXTe/5/DiZgSgbqUvG9ae0AUG+wyAXgCC/sdzuxGrDTFJa8ZlRVgjOKB5dGTE9P/TJYiMEyWZ3dlAxxlCX0hurwxRu/l+yfzWxikNx/Mp6Eq7/nxfHUgR6b9UHf/JM=
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://purl.org/dc/terms/created
2021-06-12T14:48:20.601+02:00
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAkG5c7KQkNNiInVrk1O_HJn-W7QZ8abdWUwsZyuJrij8
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs